Hicin Pharmaceutical(300584)
Search documents
医药生物行业资金流入榜:众生药业等8股净流入资金超亿元
Zheng Quan Shi Bao Wang· 2025-11-14 09:28
Market Overview - The Shanghai Composite Index fell by 0.97% on November 14, with only 4 out of the 28 sectors rising, led by the comprehensive and real estate sectors, which increased by 1.58% and 0.39% respectively [2] - The pharmaceutical and biological industry saw a slight increase of 0.17% [2] Capital Flow Analysis - The main capital outflow from the two markets totaled 81.32 billion yuan, with 5 sectors experiencing net inflows [2] - The pharmaceutical and biological sector had the highest net inflow of 680 million yuan, while the defense and military industry followed with a net inflow of 667 million yuan despite a decline of 0.44% [2] Pharmaceutical Sector Performance - Within the pharmaceutical and biological sector, 283 out of 477 stocks rose, with 15 hitting the daily limit [3] - The top three stocks with the highest net inflow were: - Zhongsheng Pharmaceutical with a net inflow of 732 million yuan - Haichen Pharmaceutical and Te Yi Pharmaceutical, both with net inflows of 299 million yuan [3] Capital Inflow and Outflow Rankings - The top stocks in terms of capital inflow included: - Zhongsheng Pharmaceutical: +9.98%, turnover rate 10.39%, inflow 731.86 million yuan - Haichen Pharmaceutical: +19.99%, turnover rate 26.19%, inflow 298.70 million yuan - Te Yi Pharmaceutical: +9.98%, turnover rate 44.11%, inflow 298.50 million yuan [4] - The stocks with the highest capital outflow included: - Fuxiang Pharmaceutical: -7.77%, turnover rate 42.68%, outflow -532.38 million yuan - Hefeng China: -7.69%, turnover rate 28.48%, outflow -338.09 million yuan - Renmin Tongtai: -10.04%, turnover rate 7.37%, outflow -125.52 million yuan [5]
海辰药业11月14日龙虎榜数据
Zheng Quan Shi Bao Wang· 2025-11-14 09:28
Group 1 - The stock of Haichen Pharmaceutical reached the daily limit, with a turnover rate of 26.19% and a transaction amount of 1.417 billion yuan, showing a volatility of 23.97% [2] - Institutional investors net sold 68.95 million yuan, while brokerage seats collectively net bought 135 million yuan [2] - The stock was listed on the daily trading board due to a price increase of 20.00% at the close [2] Group 2 - In the past six months, the stock has appeared on the trading board eight times, with an average price increase of 4.92% the next day and an average increase of 1.48% over the following five days [3] - The main capital flow for the stock today showed a net inflow of 299 million yuan, with a significant single net inflow of 397 million yuan, while large single funds experienced a net outflow of 98.05 million yuan [3] - The trading data for November 14 indicates significant buying and selling activity from various brokerage firms, with the top buying firm being Guotai Junan Securities, which bought 100.71 million yuan and sold 1.15 million yuan [3]
幽门螺杆菌概念上涨1.50%,9股主力资金净流入超3000万元
Zheng Quan Shi Bao Wang· 2025-11-14 09:28
Core Viewpoint - The Helicobacter pylori concept sector has seen a 1.50% increase, ranking fifth among concept sectors, with significant contributions from stocks like Kangzhi Pharmaceutical and Haichen Pharmaceutical reaching a 20% limit up [1][2]. Group 1: Market Performance - The Helicobacter pylori concept sector had 48 stocks rising, with notable limit-up performances from Kangzhi Pharmaceutical and Haichen Pharmaceutical [1]. - The top gainers in the sector included Kangwei Century, Anglikang, and Olin Bio, with increases of 8.60%, 5.52%, and 4.29% respectively [1]. - Conversely, the stocks with the largest declines included Zhongke Technology, Botuo Bio, and Jilin Aodong, which fell by 5.75%, 2.68%, and 2.06% respectively [1]. Group 2: Capital Inflow - The Helicobacter pylori concept sector attracted a net inflow of 1.583 billion yuan, with 34 stocks receiving net inflows, and 9 stocks exceeding 30 million yuan in net inflow [2]. - The leading stock in terms of net inflow was Zhongsheng Pharmaceutical, which saw a net inflow of 732 million yuan, followed by Haichen Pharmaceutical and Te Yi Pharmaceutical, each with 299 million yuan [2]. - The net inflow ratios for Zhongsheng Pharmaceutical, Haichen Pharmaceutical, and Kangzhi Pharmaceutical were 36.05%, 21.08%, and 20.78% respectively [3].
龙虎榜丨海辰药业20CM涨停,二游资净买入1.35亿元
Ge Long Hui A P P· 2025-11-14 09:01
| 序号 | | 交易营业部名称 | | 买入金额(万) | 占总成交比例 | | --- | --- | --- | --- | --- | --- | | | 机构专用 | | 1650次 41.88% 8 | 0.00 | 0.00% | | 2 | 机构专用 | | 1650次 41.88% ▲ | 3177.41 | 2.24% | | 3 | 机构专用 | | 1650次 41.88% | 2736.13 | 1.93% | | 4 | 机构专用 | | 1650次 41.88% | 0.00 | 0.00% | | 5 | 机构专用 | | 1650次 41.88% ▶ | 1464.97 | 1.03% | | | | (买入前5名与卖出前5名)总合计: | | 24038.97 | 16.96% | 海辰药业(300584.SZ)今日20CM涨停,换手率26.19%,成交额14.17亿元。龙虎榜数据显示,游资"中山东路"位列买一席位,净买入9956万元;"量化打板"位 列买二席位,净买入3581万元;六家机构买入1.04亿元,卖出1.73亿元,净卖出6895万元。上榜席位全天买入3.53亿元 ...
化学制药板块11月14日涨0.32%,康芝药业领涨,主力资金净流入6.8亿元
Zheng Xing Xing Ye Ri Bao· 2025-11-14 08:51
证券之星消息,11月14日化学制药板块较上一交易日上涨0.32%,康芝药业领涨。当日上证指数报收于 3990.49,下跌0.97%。深证成指报收于13216.03,下跌1.93%。化学制药板块个股涨跌见下表: 从资金流向上来看,当日化学制药板块主力资金净流入6.8亿元,游资资金净流出4.13亿元,散户资金净 流出2.67亿元。化学制药板块个股资金流向见下表: | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300584 海辰药业 | | 3.02亿 | 21.33% | -2.02 Z | -14.27% | -1.00 Z | -7.06% | | 300086 康芝药业 | | 2.55 Z | 20.57% | -1.52 Z | -12.26% | -1.03亿 | -8.31% | | 000566 海南海药 | | 2.43/Z | 37.31% | -1.15亿 | -17.60% | -1.28 乙 ...
海辰药业:公司硫化锂已完成中试线建设,正在试生产
Mei Ri Jing Ji Xin Wen· 2025-11-14 08:40
Group 1 - Company has completed the construction of the pilot line for lithium sulfide and is currently in trial production [1] - The solid-state battery adhesive is undergoing small-scale process development [1] - The company will decide on production plans based on market conditions [1] Group 2 - In 2024, the company announced plans to complete a production line for 6000 tons of VC (Vinyl Carbonate) and 3000 tons of FEC (Fluoroethylene Carbonate) [2] - The company is monitoring the significant price increase of VC and FEC and is assessing whether to start operations on the related production lines [2] - The company is also evaluating the progress of its solid-state battery lithium sulfide electrolyte and adhesive projects [2]
海辰药业:甲硫酸新斯的明注射液获得药品注册批件
Zhi Tong Cai Jing· 2025-11-14 08:24
Core Viewpoint - The approval of "Methanesulfonate Neostigmine Injection" by the National Medical Products Administration enhances the product line of the company and is expected to positively impact future performance [1] Group 1 - The company has received the drug registration certificate for "Methanesulfonate Neostigmine Injection" from the National Medical Products Administration [1] - The approval signifies that the product has passed the consistency evaluation, which is crucial for market competitiveness [1] - The introduction of this product is anticipated to improve the company's competitive capabilities and overall performance in the future [1]
11月14日连板股分析:连板股晋级率超五成 合富中国、海马汽车尾盘炸板
Xin Lang Cai Jing· 2025-11-14 08:23
Group 1 - The core viewpoint of the article highlights that the upgrade rate of stocks with consecutive gains exceeds 50%, indicating strong market interest and activity in certain sectors [1] - A total of 70 stocks hit the daily limit up, with 21 stocks classified as consecutive gainers, including 10 stocks with three or more consecutive gains [1] - The upgrade rate for consecutive gainers is reported at 55.56%, excluding ST and delisted stocks, reflecting a robust performance in the market [1] Group 2 - The article notes that local stocks related to map speculation are performing well, with Pingtan Development achieving 13 consecutive gains in 21 days, Sanmu Group with 7 gains in 10 days, and Dongbai Group with 6 gains in 8 days [1] - Defensive sectors such as coal, gas, and electricity have seen a rise due to cold weather news, with Antai Group achieving 13 gains in 22 days and Daya Energy with 2 gains in 4 days [1] - The lithium battery sector experienced a split after a previous surge, with companies like Furui Shares achieving 7 consecutive gains and Shida Shenghua with 3 consecutive gains, while others like Aoke Shares and Tianhong Lithium fell over 9% [1]
海辰药业:甲硫酸新斯的明注射液获药品注册批件
Zheng Quan Shi Bao Wang· 2025-11-14 08:16
Core Viewpoint - Haicheng Pharmaceutical has received approval from the National Medical Products Administration for the registration of Methanesulfonic Acid Neostigmine Injection, which is indicated for various medical conditions [1] Company Developments - The approved drug is an anticholinesterase agent used to counteract the residual muscle relaxation effects of non-depolarizing muscle relaxants at the end of surgery, as well as for conditions such as myasthenia gravis, postoperative functional bowel distension, and urinary retention [1] - The company has confirmed that there are no undisclosed significant matters related to the company, its controlling shareholders, or actual controllers, following an investigation into abnormal stock trading fluctuations [1]
海辰药业(300584.SZ):甲硫酸新斯的明注射液获得药品注册批件
Ge Long Hui A P P· 2025-11-14 08:15
Core Viewpoint - Haichen Pharmaceutical has received approval from the National Medical Products Administration for the drug registration certificate of Methanesulfonate Neostigmine Injection, indicating a significant advancement in its product portfolio [1] Group 1: Product Approval - The drug Methanesulfonate Neostigmine Injection is indicated for the antagonism of residual muscle relaxation effects from non-depolarizing muscle relaxants at the end of surgery [1] - It is also used for conditions such as myasthenia gravis, postoperative functional bowel distension, and urinary retention [1]